Published in Antimicrob Agents Chemother on July 01, 2004
The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A (2005) 3.84
Phage treatment of human infections. Bacteriophage (2011) 2.77
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One (2009) 2.61
Phage-host interaction: an ecological perspective. J Bacteriol (2004) 2.50
Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother (2005) 2.28
Phages in nature. Bacteriophage (2011) 2.00
Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol (2012) 1.89
Microbes have the last word. A drastic re-evaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria. EMBO Rep (2007) 1.27
Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol (2004) 1.22
Characterization of a T5-like coliphage, SPC35, and differential development of resistance to SPC35 in Salmonella enterica serovar typhimurium and Escherichia coli. Appl Environ Microbiol (2011) 1.22
A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence (2013) 1.21
Phage Therapy - Everything Old is New Again. Can J Infect Dis Med Microbiol (2006) 1.17
Comparative genomics of the T4-Like Escherichia coli phage JS98: implications for the evolution of T4 phages. J Bacteriol (2004) 1.17
Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol (2008) 1.05
Effect of bacteriophage application on Campylobacter jejuni loads in commercial broiler flocks. Appl Environ Microbiol (2013) 0.98
A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections. Viruses (2012) 0.97
Decreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problems. Microb Biotechnol (2008) 0.93
Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother (2012) 0.92
Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob Agents Chemother (2012) 0.92
Prevalence of Staphylococcus aureus and lack of its lytic bacteriophages in the anterior nares of patients and healthcare workers at a rural clinic. Clin Med Res (2010) 0.90
Staphylococcus epidermidis bacteriophages from the anterior nares of humans. Appl Environ Microbiol (2011) 0.90
Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters. Proc Natl Acad Sci U S A (2015) 0.87
Amplification and purification of T4-like escherichia coli phages for phage therapy: from laboratory to pilot scale. Appl Environ Microbiol (2013) 0.86
Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol (2014) 0.86
Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother (2011) 0.84
Phage biocontrol of enteropathogenic and shiga toxin-producing Escherichia coli in meat products. Front Cell Infect Microbiol (2013) 0.81
Ecological basis for rational phage therapy. Acta Naturae (2010) 0.81
Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model. Front Microbiol (2016) 0.79
Characterization and Testing the Efficiency of Acinetobacter baumannii Phage vB-GEC_Ab-M-G7 as an Antibacterial Agent. Front Microbiol (2016) 0.75
Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine. Sci Rep (2016) 0.75
Modification of Escherichia coli-bacteriophage interactions by surfactants and antibiotics in vitro. FEMS Microbiol Ecol (2016) 0.75
Evaluation of the efficacy of chitosan nanoparticles loaded ΦKAZ14 bacteriophage in the biological control of colibacillosis in chickens. Poult Sci (2016) 0.75
A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A (1990) 14.22
Standard reference strains of Escherichia coli from natural populations. J Bacteriol (1984) 11.16
The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull World Health Organ (1982) 7.88
A bacteriolytic agent that detects and kills Bacillus anthracis. Nature (2002) 5.63
Bacteriophage T4 genome. Microbiol Mol Biol Rev (2003) 5.20
Bacteriophage therapy. Antimicrob Agents Chemother (2001) 5.16
Traditional enteropathogenic Escherichia coli of infantile diarrhea. Rev Infect Dis (1987) 4.01
Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science (2001) 3.72
Prospective study of diarrheal illnesses in northeastern Brazil: patterns of disease, nutritional impact, etiologies, and risk factors. J Infect Dis (1983) 3.65
Survival and implantation of Escherichia coli in the intestinal tract. Infect Immun (1983) 3.49
Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A (1996) 3.34
Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol (1999) 3.11
Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A (2001) 3.10
Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol (1983) 2.82
The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol (1987) 2.76
Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun (2002) 2.52
Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis (1990) 2.52
Complete genome sequence of the broad-host-range vibriophage KVP40: comparative genomics of a T4-related bacteriophage. J Bacteriol (2003) 2.51
Spatial distribution of Escherichia coli in the mouse large intestine inferred from rRNA in situ hybridization. Infect Immun (1994) 2.40
Bacteriophage therapy. Annu Rev Microbiol (2001) 2.39
Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin-treated mice. J Bacteriol (1995) 2.18
Bacteriophages show promise as antimicrobial agents. J Infect (1998) 2.16
Controlled study of Escherichia coli diarrheal infections in Bangladeshi children. J Clin Microbiol (1995) 2.15
Phylogeny of the major head and tail genes of the wide-ranging T4-type bacteriophages. J Bacteriol (2001) 2.14
Case-control study of endemic diarrheal disease in Thai children. J Infect Dis (1989) 2.14
The genome of the pseudo T-even bacteriophages, a diverse group that resembles T4. J Mol Biol (1997) 2.13
Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) (1999) 2.10
Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun (2003) 2.06
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol (1998) 2.03
Bacteriophage therapy. Stalin's forgotten cure. Science (2002) 1.93
A catalogue of T4-type bacteriophages. Arch Virol (1997) 1.72
An Escherichia coli MG1655 lipopolysaccharide deep-rough core mutant grows and survives in mouse cecal mucus but fails to colonize the mouse large intestine. Infect Immun (2003) 1.71
Identification of coccoid Escherichia coli BJ4 cells in the large intestine of streptomycin-treated mice. Infect Immun (1993) 1.66
Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl Environ Microbiol (1999) 1.55
Bacteriophage distribution in human faeces: continuous survey of healthy subjects and patients with internal and leukaemic diseases. J Gen Virol (1983) 1.42
Evolution of T4-related phages. Virus Genes (1995) 1.39
Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun (2002) 1.37
Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother (2003) 1.33
Etiology of childhood diarrhea in Korea. J Clin Microbiol (1989) 1.29
A comparative study of specific gene probes and standard bioassays to identify diarrhoeagenic Escherichia coli in paediatric patients with diarrhoea in Bangladesh. J Med Microbiol (1992) 1.21
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group. J Infect Dis (1999) 1.20
Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis (2002) 1.09
Clinical trials of improved oral rehydration salt formulations: a review. Bull World Health Organ (1994) 1.07
Phage antibacterials make a comeback. Nat Biotechnol (2001) 1.05
The new antibiotics. Nat Biotechnol (1999) 1.00
Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J (2002) 0.97
Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: a double-blind, placebo-controlled, clinical trial. Scand J Gastroenterol (2000) 0.96
Bacteriophage T4 genome. Microbiol Mol Biol Rev (2003) 5.20
Prophage genomics. Microbiol Mol Biol Rev (2003) 4.49
Tackling antibiotic resistance. Nat Rev Microbiol (2011) 3.95
Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol (2002) 3.02
The impact of prophages on bacterial chromosomes. Mol Microbiol (2004) 2.72
Phage as agents of lateral gene transfer. Curr Opin Microbiol (2003) 2.68
Phage-host interaction: an ecological perspective. J Bacteriol (2004) 2.50
Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother (2005) 2.28
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The dilemma of phage taxonomy illustrated by comparative genomics of Sfi21-like Siphoviridae in lactic acid bacteria. J Bacteriol (2002) 1.71
Comparative genomics of phages and prophages in lactic acid bacteria. Antonie Van Leeuwenhoek (2002) 1.71
Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis. J Bacteriol (2008) 1.62
Similarity and differences in the Lactobacillus acidophilus group identified by polyphasic analysis and comparative genomics. J Bacteriol (2006) 1.46
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol (2012) 1.39
Lactobacillus plantarum bacteriophage LP65: a new member of the SPO1-like genus of the family Myoviridae. J Bacteriol (2004) 1.32
The complete genomes of Lactobacillus plantarum and Lactobacillus johnsonii reveal extensive differences in chromosome organization and gene content. Microbiology (2004) 1.31
Transcription mapping as a tool in phage genomics: the case of the temperate Streptococcus thermophilus phage Sfi21. Virology (2002) 1.31
Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the "N4-like viruses". Virology (2010) 1.30
The prophage sequences of Lactobacillus plantarum strain WCFS1. Virology (2003) 1.28
Genome analysis of an inducible prophage and prophage remnants integrated in the Streptococcus pyogenes strain SF370. Virology (2002) 1.23
Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol (2004) 1.22
Comparative genomics of the T4-Like Escherichia coli phage JS98: implications for the evolution of T4 phages. J Bacteriol (2004) 1.17
Integration and distribution of Lactobacillus johnsonii prophages. J Bacteriol (2003) 1.14
Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology (2012) 1.12
Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics (2005) 1.11
Transcription analysis of Streptococcus thermophilus phages in the lysogenic state. Virology (2002) 1.06
Genome analysis of phage JS98 defines a fourth major subgroup of T4-like phages in Escherichia coli. J Bacteriol (2007) 1.06
T4 phages against Escherichia coli diarrhea: potential and problems. Virology (2009) 1.06
Gene expression of commensal Lactobacillus johnsonii strain NCC533 during in vitro growth and in the murine gut. J Bacteriol (2007) 1.02
Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology (2013) 1.01
The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One (2013) 1.00
Campylobacter jejuni group III phage CP81 contains many T4-like genes without belonging to the T4-type phage group: implications for the evolution of T4 phages. J Virol (2011) 1.00
The prophages of Lactobacillus johnsonii NCC 533: comparative genomics and transcription analysis. Virology (2004) 1.00
Nasopharyngeal microbiota in healthy children and pneumonia patients. J Clin Microbiol (2014) 1.00
A Mesocosm of Lactobacillus johnsonii, Bifidobacterium longum, and Escherichia coli in the mouse gut. DNA Cell Biol (2009) 0.98
In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology (2009) 0.98
Decreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problems. Microb Biotechnol (2008) 0.93
Infant gut microbiota is protective against cow's milk allergy in mice despite immature ileal T-cell response. FEMS Microbiol Ecol (2012) 0.93
Quality and safety requirements for sustainable phage therapy products. Pharm Res (2015) 0.93
Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol (2011) 0.93
Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol (2007) 0.92
The role of prophage for genome diversification within a clonal lineage of Lactobacillus johnsonii: characterization of the defective prophage LJ771. J Bacteriol (2008) 0.91
DNA-binding activity of the Streptococcus thermophilus phage Sfi21 repressor. Virology (2002) 0.87
Amplification and purification of T4-like escherichia coli phages for phage therapy: from laboratory to pilot scale. Appl Environ Microbiol (2013) 0.86
Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol (2014) 0.86
Food and gut microbes for thoughts. Microb Biotechnol (2009) 0.78
Temporal transcription map of the virulent Streptococcus thermophilus bacteriophage Sfi19. Appl Environ Microbiol (2004) 0.78
Occurrence of Salmonella-specific bacteriophages in swine feces collected from commercial farms. Foodborne Pathog Dis (2010) 0.77
Recent advances in the expression, evolution, and dynamics of prokaryotic genomes. J Bacteriol (2007) 0.76
Anecdotal, historical and critical commentaries on genetics. Gisela Mosig. Genetics (2004) 0.75